VAS
GBT

Vestmark Advisory Solutions’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Vestmark Advisory Solutions’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,644
Closed -$564K – 890
2022
Q2 		$564K Buy
17,644
+4,975
+39% +$146K 0.03% 516
2022
Q1 		$439K Buy
12,669
+3,892
+44% +$116K 0.02% 585
2021
Q4 		$257K Buy
+8,777
New +$272K 0.01% 759

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vestmark Advisory Solutions's GBT Position: Q3 2022 in Review

Vestmark Advisory Solutions sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 17,644 shares — an estimated $564K sold.

Vestmark Advisory Solutions first reported a position in GBT in Q4 2021 and held it in 3 quarters. The position peaked at $564K in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Vestmark Advisory Solutions reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Vestmark Advisory Solutions sold 17,644 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $564K.
  • Vestmark Advisory Solutions first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 3 quarters.
  • Vestmark Advisory Solutions's Global Blood Therapeutics, Inc. position peaked at $564K in Q2 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Vestmark Advisory Solutions's 13F filing for Q3 2022, filed 3 Nov 2022.